Search results

Discover how Altasciences reduced clinical trial start-up timelines by 70%, initiating the first dose of a Phase I MAD study in just 3.5 weeks.

Explore Canada `s advantages for early-phase clinical trials: streamlined regulatory pathways, diverse participant pool, and cost-effectiveness.

This Q&A with Dr. Norbert Makori and Pierre Jolicoeur reveals insights on preclinical gene therapy studies and capabilities at Altasciences’ site in Seattle

Explore the process required for manufacturing a highly potent API for an ophthalmic indication, based on a case study involving loteprednol etabonate, a topical corticosteroid used to treat eye inflammations.